Bioprinting Human Tissue: What Works in the Lab, and What Would It Take to Reach Patients?

The popular picture goes like this: a printer hums, a nozzle glides back and forth, and a few hours later a pink, beating heart sits in a dish, ready for a patient. It is a wonderful image. It is also, for now, science fiction. No bioprinted solid organ has been transplanted into a person as a replacement.

The real story is slower and, in some ways, more interesting. Bioprinting has already produced remarkable tissue structures in the lab and in animals, early products have entered small human studies, and a U.S. government program is now funding teams that aim to print organs. Understanding the gap between those milestones and a routine transplant is the whole point of this article.

What bioprinting actually is

Bioprinting is a form of 3D printing that deposits living cells, usually mixed into a bioink—a printable material, often a water-rich gel called a hydrogel—layer by layer to build a three-dimensional structure. The aim is to arrange cells and supporting materials roughly the way they are arranged in real tissue.

A widely cited 2014 review in Nature Biotechnology, “3D bioprinting of tissues and organs”, laid out why this is harder than printing plastic: researchers must choose materials, cell types, and growth and differentiation factors, and cope with the fact that living cells are sensitive to the printing process itself. The authors noted that bioprinting had been used in research to build structures including skin, bone, vascular grafts, tracheal splints, heart tissue and cartilage—and that success requires combining engineering, biomaterials science, cell biology, physics and medicine.

What already reaches patients: printing without living cells

It helps to separate bioprinting from ordinary medical 3D printing, which is already routine. The FDA’s page on 3D printing of medical devices lists orthopedic and cranial implants, surgical instruments, dental restorations such as crowns, and external prosthetics among devices produced this way, and notes that 3D printing allows patient-specific devices matched to a person’s anatomy.

Those are not living tissues. Once you add living cells, the product usually becomes a biologic or a combination product, and the FDA notes that 3D-printed products can fall under its device, biologics or drug centres. That shift brings a very different evidence burden. For more on the device side of the story, see The Next Medical Device Wave.

The central problem: keeping cells alive

Every cell in your body is close to a blood vessel for a reason: oxygen and nutrients can only diffuse a short distance through tissue. A printed block of cells thicker than that limit starves in the middle.

A 2016 study in Nature Biotechnology from the Wake Forest Institute for Regenerative Medicine tackled this with an integrated tissue-organ printer. The team printed jawbone and skull-bone shapes, cartilage and skeletal muscle, combining cell-laden hydrogels with biodegradable polymers for strength. They built in microchannels to help nutrients reach printed cells, which they described as a way to overcome the diffusion limit of 100–200 micrometres for cell survival in engineered tissues. The constructs were tested in animals—a preclinical result.

In 2019, researchers publishing in Science showed a different approach to the plumbing problem. Using projection stereolithography—printing with patterned light—and food dyes as safe light-absorbing additives, they created intricate, interwoven vessel networks inside hydrogels. One design mimicked a lung air sac and oxygenated human red blood cells during repeated “breathing” cycles; in another experiment, gels carrying liver cells were implanted in mice with chronic liver injury and showed signs of function. Again: impressive engineering, tested in the lab and in animals.

Printing the shape of an organ is the easy part. Printing something that stays alive, connects to the body and does the organ’s job for decades is the problem.

First steps into people

A small number of bioprinted products have reached clinical testing. One example is AuriNovo, from 3DBio Therapeutics, designed for people born with microtia, a condition in which the outer ear is underdeveloped. According to its trial registry record, it is a patient-specific construct made with the patient’s own cartilage cells, tested in an open-label Phase 1/2a study. The registry lists the study as terminated with very small enrollment, and an independent tracker of U.S. trial reporting shows no results posted as of September 2026. That leaves the key clinical questions—durability, safety, how well the ear holds its shape—publicly unanswered.

That is a common pattern in early regenerative medicine: a technically striking first-in-human case, followed by a long, uncertain path to evidence.

The organ moonshot

The most ambitious effort in the U.S. is the Advanced Research Projects Agency for Health’s PRINT program, which aims to 3D-print personalized, on-demand organs that would not require immunosuppressive drugs. ARPA-H frames the need starkly: patients face chronic organ shortages and long waiting lists, and thousands in the U.S. die each year waiting for a match.

In January 2026, ARPA-H announced awards of up to $176.8 million over five years to teams at Carnegie Mellon University, Wake Forest University, the Wyss Institute, the University of California San Diego and UT Southwestern, working mainly on liver and kidney tissue. The agency itself says success requires major breakthroughs in cell manufacturing, bioreactor design and 3D printing. It is a research program, not a product—its value is that it names the hardest problems and funds people to attack them.

What would it take to reach patients?

For bioprinted tissue to become a routine treatment, several problems have to be solved together:

1. Blood supply: printed vessels must connect to the patient’s circulation and stay open.
2. Cells at scale: organs need enormous numbers of the right cells, made consistently and safely.
3. Maturation: freshly printed tissue is immature; it may need time in a bioreactor, a device that feeds and conditions growing tissue.
4. Immune compatibility: avoiding rejection without lifelong drugs is a core goal, and a hard one.
5. Long-term safety: implanted living cells must not grow where they shouldn’t or fail over years.
6. Evidence and regulation: randomized or well-controlled human trials, long follow-up, and manufacturing standards for living products.
7. Cost and access: a personalized organ that only a few hospitals can make would help only a few people.

Meanwhile, some of bioprinting’s nearest-term value may be in the lab rather than the clinic: printed human tissue models for testing drugs. That overlaps with the rise of organoids, which we explore in Organoids and Lab-Grown Models. Industry news on printers, materials and companies is covered in depth by our sister site Bioprinting World.

How to read the next bioprinting headline

• Is it a shape, a living tissue, or a functioning organ?
• Was it tested in a dish, in animals, or in people—and how many?
• How long was it followed, and did it connect to blood supply?
• Is there a registered trial, and have results been posted?

Asking those questions is not cynicism; it is how you tell a milestone from a promise. Our guide on how to read a biotech breakthrough goes further, and if you want to understand the building blocks being printed, try Build a Cell.